Antenatal magnesium sulphate for protection of the preterm brain in women at risk preterm delivery at 28-36 weeks gestation

Antenatal magnesium sulphate for short term neuroprotection among women at risk of preterm delivery at 28 to 36 weeks gestation.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202404671084461

Enrollment

Registered

2024-04-19

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases

Interventions

Magnesium sulphate

No intervention was given to the control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pregnant women at risk of preterm delivery between 28 to 36weeks of gestation Preterm prelabour rupture of membranes Preterm labour Planned preterm birth for maternal or fetal indication

Exclusion criteria

Exclusion criteria: Congenital anomaly in the foetus Second stage of labour Maternal hypotension Women who received MgSO4 within the last 12 hrs

Design outcomes

Primary

Measure	Time frame
Perinatal death and intraventricular haemorrhage in the preterm newborns	—

Secondary

Measure	Time frame
Apgar scores at birth, type of resuscitation at birth, need for admission of the newborn, hypoxic ischaemic encephalopathy, anaemia requiring blood transfusion will serve as secondary outcomes	—

Countries

Nigeria

Contacts

Public ContactFashie Patrick

Public enquiries

andrewfashie@yahoo.co.uk+2348063399886

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026